HYDROXYUREA CAPSULES USP

Manufacturer
Physicians Total Care, Inc.
Effective date
2012-06-01
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 20:15:20

Label at a glance#

ProductHYDROXYUREA
Active ingredientHYDROXYUREA
Label structure13 sections

Indications and uses

Significant tumor response to hydroxyurea capsules USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. Hydroxyurea, USP used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip.

Dosage and administration

Procedures for proper handling and disposal of cytotoxic drugs should be considered. Several guidelines on this subject have been published. 1-4 To minimize the risk of dermal exposure, always wear impervious gloves when handling bottles containing hydroxyurea capsules. Hydroxyurea capsules should not be opened. Personnel should avoid exposure to crushed or opened capsules. If contact with crushed or opened capsul...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DESCRIPTION

DESCRIPTION SECTION

Hydroxyurea capsules USP are an antineoplastic agent available for oral use as capsules providing 500 mg hydroxyurea, USP. Inactive ingredients: anhydrous citric acid, benzyl alcohol, black iron oxide, butylparaben, carboxymethylcellulose sodium, D & C red no. 28, D & C yellow no. 10 aluminum lake, dibasic sodium phosphate, edetate calcium disodium, FD & C blue no. 1, FD & C blue no. 1 aluminum lake, FD & C blue no. 2 aluminum lake, FD & C red no. 40, FD & C red no. 40 aluminum lake, gelatin, lactose monohydrate, magnesium stearate, methylparaben, pharmaceutical glaze, propylparaben, propylene glycol, red iron oxide, sodium lauryl sulfate, sodium propionate, and titanium dioxide.

Hydroxyurea is an essentially tasteless, white crystalline powder. Its structural formula is:

CH4N2O2 M.W. 76.05
CH4N2O2 M.W. 76.05

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Mechanism of Action

SPL UNCLASSIFIED SECTION

The precise mechanism by which hydroxyurea produces its antineoplastic effects cannot, at present, be described. However, the reports of various studies in tissue culture in rats and humans lend support to the hypothesis that hydroxyurea causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or of protein. This hypothesis explains why, under certain conditions, hydroxyurea may induce teratogenic effects.

Three mechanisms of action have been postulated for the increased effectiveness of concomitant use of hydroxyurea therapy with irradiation on squamous cell (epidermoid) carcinomas of the head and neck. In vitro studies utilizing Chinese hamster cells suggest that hydroxyurea (1) is lethal to normally radioresistant S-stage cells, and (2) holds other cells of the cell cycle in the G1 or pre-DNA synthesis stage where they are most susceptible to the effects of irradiation. The third mechanism of action has been theorized on the basis of in vitro studies of HeLa cells: it appears that hydroxyurea, by inhibition of DNA synthesis, hinders the normal repair process of cells damaged but not killed by irradiation, thereby decreasing their survival rate; RNA and protein syntheses have shown no alteration.

Pharmacokinetics

SPL UNCLASSIFIED SECTION

Absorption

SPL UNCLASSIFIED SECTION

Hydroxyurea is readily absorbed after oral administration. Peak plasma levels are reached in 1 to 4 hours after an oral dose. With increasing doses, disproportionately greater mean peak plasma concentrations and AUCs are observed.

There are no data on the effect of food on the absorption of hydroxyurea.

Distribution

SPL UNCLASSIFIED SECTION

Hydroxyurea distributes rapidly and widely in the body with an estimated volume of distribution approximating total body water.

Plasma to ascites fluid ratios range from 2:1 to 7.5:1. Hydroxyurea concentrates in leukocytes and erythrocytes.

Metabolism

SPL UNCLASSIFIED SECTION

Up to 60% of an oral dose undergoes conversion through metabolic pathways that are not fully characterized. One pathway is probably saturable hepatic metabolism. Another minor pathway may be degradation by urease found in intestinal bacteria. Acetohydroxamic acid was found in the serum of three leukemic patients receiving hydroxyurea and may be formed from hydroxylamine resulting from action of urease on hydroxyurea.

Excretion

SPL UNCLASSIFIED SECTION

Excretion of hydroxyurea in humans is likely a linear first-order renal process.

Special Populations

SPL UNCLASSIFIED SECTION

Geriatric, Gender, Race

SPL UNCLASSIFIED SECTION

No information is available regarding pharmacokinetic differences due to age, gender, or race.

Pediatric

SPL UNCLASSIFIED SECTION

No pharmacokinetic data are available in pediatric patients treated with hydroxyurea.

Renal Insufficiency

SPL UNCLASSIFIED SECTION

As renal excretion is a pathway of elimination, consideration should be given to decreasing the dosage of hydroxyurea in patients with renal impairment. In adult patients with sickle cell disease, an open-label, non-randomized, single-dose, multicenter study was conducted to assess the influence of renal function on the pharmacokinetics of hydroxyurea. Patients in the study with normal renal function (creatinine clearance [CrCl] > 80 mL/min), mild (CrCl 50 to 80 mL/min), moderate (CrCl = 30 to < 50 mL/min), or severe (< 30 mL/min) renal impairment received hydroxyurea as a single oral dose of 15 mg/kg, achieved by using combinations of the 200 mg, 300 mg, or 400 mg capsules. Patients with end-stage renal disease (ESRD) received two doses of 15 mg/kg separated by 7 days, the first was given following a 4 hour hemodialysis session, the second prior to hemodialysis. In this study, the mean exposure (AUC) in patients whose creatinine clearance was < 60 mL/min (or ESRD) was approximately 64% higher than in patients with normal renal function. The results suggest that the initial dose of hydroxyurea should be reduced when used to treat patients with renal impairment (see PRECAUTIONS and DOSAGE AND ADMINISTRATION). Close monitoring of hematologic parameters is advised in these patients.

Hepatic Insufficiency

SPL UNCLASSIFIED SECTION

There are no data that support specific guidance for dosage adjustment in patients with hepatic impairment. Close monitoring of hematologic parameters is advised in these patients.

Drug Interactions

SPL UNCLASSIFIED SECTION

There are no data on concomitant use of hydroxyurea with other drugs in humans.

Animal Pharmacology and Toxicology

SPL UNCLASSIFIED SECTION

The oral LD50 of hydroxyurea is 7330 mg/kg in mice and 5780 mg/kg in rats, given as a single dose.

In subacute and chronic toxicity studies in the rat, the most consistent pathological findings were an apparent dose-related mild to moderate bone marrow hypoplasia as well as pulmonary congestion and mottling of the lungs. At the highest dosage levels (1260 mg/kg/day for 37 days, then 2520 mg/kg/day for 40 days), testicular atrophy with absence of spermatogenesis occurred; in several animals, hepatic cell damage with fatty metamorphosis was noted. In the dog, mild to marked bone marrow depression was a consistent finding except at the lower dosage levels. Additionally, at the higher dose levels (140 to 420 mg or 140 to 1260 mg/kg/week given 3 or 7 days weekly for 12 weeks), growth retardation, slightly increased blood glucose values, and hemosiderosis of the liver or spleen were found; reversible spermatogenic arrest was noted. In the monkey, bone marrow depression, lymphoid atrophy of the spleen, and degenerative changes in the epithelium of the small and large intestines were found. At the higher, often lethal, doses (400 to 800 mg/kg/day for 7 to 15 days), hemorrhage and congestion were found in the lungs, brain, and urinary tract. Cardiovascular effects (changes in heart rate, blood pressure, orthostatic hypotension, EKG changes) and hematological changes (slight hemolysis, slight methemoglobinemia) were observed in some species of laboratory animals at doses exceeding clinical levels.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Significant tumor response to hydroxyurea capsules USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary.

Hydroxyurea, USP used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Hydroxyurea is contraindicated in patients with marked bone marrow depression, i.e., leukopenia (< 2500 WBC) or thrombocytopenia (< 100,000), or severe anemia.

Hydroxyurea capsules are contraindicated in patients who have demonstrated a previous hypersensitivity to hydroxyurea or any other component of its formulation.

WARNINGS

WARNINGS SECTION

Treatment with hydroxyurea should not be initiated if bone marrow function is markedly depressed (see CONTRAINDICATIONS). Bone marrow suppression may occur, and leukopenia is generally its first and most common manifestation. Thrombocytopenia and anemia occur less often and are seldom seen without a preceding leukopenia. However, the recovery from myelosuppression is rapid when therapy is interrupted. It should be borne in mind that bone marrow depression is more likely in patients who have previously received radiotherapy or cytotoxic cancer chemotherapeutic agents; hydroxyurea should be used cautiously in such patients.

Patients who have received irradiation therapy in the past may have an exacerbation of postirradiation erythema.

In HIV-infected patients during therapy with hydroxyurea and didanosine, with or without stavudine, fatal and nonfatal pancreatitis have occurred. Hepatotoxicity and hepatic failure resulting in death have been reported during postmarketing surveillance in HIV-infected patients treated with hydroxyurea and other antiretroviral agents. Fatal hepatic events were reported most often in patients treated with the combination of hydroxyurea, didanosine, and stavudine. This combination should be avoided.

Peripheral neuropathy, which was severe in some cases, has been reported in HIV-infected patients receiving hydroxyurea in combination with antiretroviral agents, including didanosine, with or without stavudine.

Severe anemia must be corrected before initiating therapy with hydroxyurea.

Erythrocytic abnormalities: megaloblastic erythropoiesis, which is self-limiting, is often seen early in the course of hydroxyurea therapy. The morphologic change resembles pernicious anemia, but is not related to vitamin B12 or folic acid deficiency. Hydroxyurea may also delay plasma iron clearance and reduce the rate of iron utilization by erythrocytes, but it does not appear to alter the red blood cell survival time.

Elderly patients may be more sensitive to the effects of hydroxyurea, and may require a lower dose regimen (see PRECAUTIONS, Geriatric Use).

In patients receiving long-term hydroxyurea for myeloproliferative disorders, such as polycythemia vera and thrombocythemia, secondary leukemia has been reported. It is unknown whether this leukemogenic effect is secondary to hydroxyurea or associated with the patient’s underlying disease.

Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea. These vasculitic toxicities were reported most often in patients with a history of, or currently receiving, interferon therapy. Due to potentially severe clinical outcomes for the cutaneous vasculitic ulcers reported in patients with myeloproliferative disease, hydroxyurea should be discontinued if cutaneous vasculitic ulcerations develop and alternative cytoreductive agents should be initiated as indicated.

Carcinogenesis and Mutagenesis

SPL UNCLASSIFIED SECTION

Hydroxyurea is genotoxic in a wide range of test systems and is thus presumed to be a human carcinogen. In patients receiving long-term hydroxyurea for myeloproliferative disorders, such as polycythemia vera and thrombocythemia, secondary leukemia has been reported. It is unknown whether this leukemogenic effect is secondary to hydroxyurea or is associated with the patient’s underlying disease. Skin cancer has also been reported in patients receiving long-term hydroxyurea.

Conventional long-term studies to evaluate the carcinogenic potential of hydroxyurea have not been performed. However, intraperitoneal administration of 125 to 250 mg/kg hydroxyurea (about 0.6 to 1.2 times the maximum recommended human oral daily dose on a mg/m2 basis) thrice weekly for 6 months to female rats increased the incidence of mammary tumors in rats surviving to 18 months compared to control. Hydroxyurea is mutagenic in vitro to bacteria, fungi, protozoa, and mammalian cells. Hydroxyurea is clastogenic in vitro (hamster cells, human lymphoblasts) and in vivo (SCE assay in rodents, mouse micronucleus assay). Hydroxyurea causes the transformation of rodent embryo cells to a tumorigenic phenotype.

Pregnancy

SPL UNCLASSIFIED SECTION

Drugs which affect DNA synthesis, such as hydroxyurea, may be potential mutagenic agents. The physician should carefully consider this possibility before administering this drug to male or female patients who may contemplate conception.

Hydroxyurea capsules can cause fetal harm when administered to a pregnant woman. Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs, and monkeys at doses within 1 fold of the human dose given on a mg/m2 basis. Hydroxyurea is embryotoxic and causes fetal malformations (partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, missing lumbar vertebrae) at 180 mg/kg/day (about 0.8 times the maximum recommended human daily dose on a mg/m2 basis) in rats and at 30 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m2 basis) in rabbits. Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays. Hydroxyurea crosses the placenta. Single doses of ≥ 375 mg/kg (about 1.7 times the maximum recommended human daily dose on a mg/m2 basis) to rats caused growth retardation and impaired learning ability. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.

PRECAUTIONS

PRECAUTIONS SECTION

General 

SPL UNCLASSIFIED SECTION

Therapy with hydroxyurea requires close supervision. The complete status of the blood, including bone marrow examination, if indicated, as well as kidney function and liver function should be determined prior to, and repeatedly during, treatment. The determination of the hemoglobin level, total leukocyte counts, and platelet counts should be performed at least once a week throughout the course of hydroxyurea therapy. If the white blood cell count decreases to less than 2500/mm3, or the platelet count to less than 100,000/mm3, therapy should be interrupted until the values rise significantly toward normal levels. Severe anemia, if it occurs, should be managed without interrupting hydroxyurea therapy.

Hydroxyurea should be used with caution in patients with marked renal dysfunction (see CLINICAL PHARMACOLOGY, Special Populations and DOSAGE AND ADMINISTRATION).

Hydroxyurea is not indicated for the treatment of HIV infection; however, if HIV-infected patients are treated with hydroxyurea, and in particular, in combination with didanosine and/or stavudine, close monitoring for signs and symptoms of pancreatitis is recommended. Patients who develop signs and symptoms of pancreatitis should permanently discontinue therapy with hydroxyurea (see WARNINGS and ADVERSE REACTIONS).

An increased risk of hepatotoxicity, which may be fatal, may occur in patients treated with hydroxyurea, and in particular, in combination with didanosine and stavudine. This combination should be avoided.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

See WARNINGS for Carcinogenesis and Mutagenesis information.

Impairment of Fertility

SPL UNCLASSIFIED SECTION

Hydroxyurea administered to male rats at 60 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m2 basis) produced testicular atrophy, decreased spermatogenesis, and significantly reduced their ability to impregnate females.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

Pregnancy Category D

(See WARNINGS.)

Nursing Mothers

NURSING MOTHERS SECTION

Hydroxyurea is excreted in human milk.

Because of the potential for serious adverse reactions with hydroxyurea, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

GERIATRIC USE SECTION

Elderly patients may be more sensitive to the effects of hydroxyurea, and may require a lower dose regimen.

This drug is known to be excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION, Renal Insufficiency).

Drug Interactions

DRUG INTERACTIONS SECTION

Prospective studies on the potential for hydroxyurea to interact with other drugs have not been performed.

Concurrent use of hydroxyurea and other myelosuppressive agents or radiation therapy may increase the likelihood of bone marrow depression or other adverse events (see WARNINGS and ADVERSE REACTIONS).

Studies have shown that there is an analytical interference of hydroxyurea with the enzymes (urease, uricase, and lactate dehydrogenase) used in the determination of urea, uric acid and lactic acid, rendering falsely elevated results of these in patients treated with hydroxyurea.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Hydroxyurea capsules are a medication that must be handled with care. People who are not taking hydroxyurea capsules should not be exposed to it. To decrease the risk of exposure, wear disposable gloves when handling hydroxyurea capsules or bottles containing hydroxyurea capsules. Anyone handling hydroxyurea capsules should wash their hands before and after contact with the bottle or capsules. If the powder from the capsule is spilled, it should be wiped up immediately with a damp disposable towel and discarded in a closed container, such as a plastic bag. The medication should be kept away from children and pets. Contact your doctor for instructions on how to dispose of outdated capsules.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Reported adverse reactions are bone marrow depression (leukopenia, anemia, and thrombocytopenia), gastrointestinal symptoms (stomatitis, anorexia, nausea, vomiting, diarrhea, and constipation), and dermatological reactions such as maculopapular rash, skin ulceration, dermatomyositis-like skin changes, peripheral and facial erythema. Hyperpigmentation, atrophy of skin and nails, scaling, and violet papules have been observed in some patients after several years of long-term daily maintenance therapy with hydroxyurea capsules. Skin cancer has been reported. Cutaneous vasculitic toxicities, including vasculitic ulcerations and gangrene, have occurred in patients with myeloproliferative disorders during therapy with hydroxyurea. These vasculitic toxicities were reported most often in patients with a history of, or currently receiving, interferon therapy (see WARNINGS). Dysuria and alopecia have been reported. Large doses may produce moderate drowsiness. Neurological disturbances have occurred and were limited to headache, dizziness, disorientation, hallucinations, and convulsions. Hydroxyurea capsules may cause temporary impairment of renal tubular function accompanied by elevations in serum uric acid, blood urea nitrogen (BUN), and creatinine levels. Abnormal bromsulphalein (BSP) retention has been reported. Fever, chills, malaise, edema, asthenia, and elevation of hepatic enzymes have also been reported.

Adverse reactions observed with combined hydroxyurea and irradiation therapy are similar to those reported with the use of hydroxyurea or radiation treatment alone. These effects primarily include bone marrow depression (anemia and leukopenia), gastric irritation, and mucositis. Almost all patients receiving an adequate course of combined hydroxyurea and irradiation therapy will demonstrate concurrent leukopenia. Platelet depression (< 100,000 cells/mm3) has occurred in the presence of marked leukopenia. Hydroxyurea capsules may potentiate some adverse reactions usually seen with irradiation alone, such as gastric distress and mucositis.

The association of hydroxyurea with the development of acute pulmonary reactions consisting of diffuse pulmonary infiltrates, fever, and dyspnea has been reported. Pulmonary fibrosis also has been reported.

In HIV-infected patients who received hydroxyurea in combination with antiretroviral agents, in particular, didanosine plus stavudine, fatal and nonfatal pancreatitis and hepatotoxicity, and severe peripheral neuropathy have been reported. Patients treated with hydroxyurea in combination with didanosine, stavudine, and indinavir in Study ACTG 5025 showed a median decline in CD4 cells of approximately 100/mm3 (see WARNINGS and PRECAUTIONS).

OVERDOSAGE

OVERDOSAGE SECTION

Acute mucocutaneous toxicity has been reported in patients receiving hydroxyurea at dosages several times the therapeutic dose. Soreness, violet erythema, edema on palms and soles followed by scaling of hands and feet, severe generalized hyperpigmentation of the skin, and stomatitis have also been observed.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Procedures for proper handling and disposal of cytotoxic drugs should be considered. Several guidelines on this subject have been published.1-4

To minimize the risk of dermal exposure, always wear impervious gloves when handling bottles containing hydroxyurea capsules. Hydroxyurea capsules should not be opened. Personnel should avoid exposure to crushed or opened capsules. If contact with crushed or opened capsules occurs, wash immediately and thoroughly. More information is available in the references listed below.

Because of the rarity of melanoma, resistant chronic myelocytic leukemia, carcinoma of the ovary, and carcinomas of the head and neck in pediatric patients, dosage regimens have not been established.

All dosage should be based on the patient’s actual or ideal weight, whichever is less. Concurrent use of hydroxyurea capsules with other myelosuppressive agents may require adjustment of dosages.

Since hydroxyurea may raise the serum uric acid level, dosage adjustment of uricosuric medication may be necessary.

Solid Tumors

SPL UNCLASSIFIED SECTION

Intermittent Therapy

SPL UNCLASSIFIED SECTION

80 mg/kg administered orally as a single dose every third day

Continuous Therapy

SPL UNCLASSIFIED SECTION

20 to 30 mg/kg administered orally as a single dose daily

Concomitant Therapy with Irradiation

SPL UNCLASSIFIED SECTION

Carcinoma of the head and neck

SPL UNCLASSIFIED SECTION

80 mg/kg administered orally as a single dose every third day

Administration of hydroxyurea should begin at least seven days before initiation of irradiation and continued during radiotherapy as well as indefinitely afterwards provided that the patient may be kept under adequate observation and evidences no unusual or severe reactions.

Resistant Chronic Myelocytic Leukemia

SPL UNCLASSIFIED SECTION

Until the intermittent therapy regimen has been evaluated, CONTINUOUS therapy (20 to 30 mg/kg administered orally as a single dose daily) is recommended.

An adequate trial period for determining the antineoplastic effectiveness of hydroxyurea is six weeks of therapy. When there is regression in tumor size or arrest in tumor growth, therapy should be continued indefinitely. Therapy should be interrupted if the white blood cell count drops below 2500/mm3, or the platelet count below 100,000/mm3. In these cases, the counts should be reevaluated after three days, and therapy resumed when the counts return to acceptable levels. Since the hematopoietic rebound is prompt, it is usually necessary to omit only a few doses. If prompt rebound has not occurred during combined hydroxyurea capsules and irradiation therapy, irradiation may also be interrupted. However, the need for postponement of irradiation has been rare; radiotherapy has usually been continued using the recommended dosage and technique. Severe anemia, if it occurs, should be corrected without interrupting hydroxyurea therapy. Because hematopoiesis may be compromised by extensive irradiation or by other antineoplastic agents, it is recommended that hydroxyurea be administered cautiously to patients who have recently received extensive radiation therapy or chemotherapy with other cytotoxic drugs.

Pain or discomfort from inflammation of the mucous membranes at the irradiated site (mucositis) is usually controlled by measures such as topical anesthetics and orally administered analgesics. If the reaction is severe, hydroxyurea therapy may be temporarily interrupted; if it is extremely severe, irradiation dosage may, in addition, be temporarily postponed. However, it has rarely been necessary to terminate these therapies.

Severe gastric distress, such as nausea, vomiting, and anorexia, resulting from combined therapy may usually be controlled by temporary interruption of hydroxyurea administration.

Renal Insufficiency

SPL UNCLASSIFIED SECTION

As renal excretion is a pathway of elimination, consideration should be given to decreasing the dosage of hydroxyurea capsules in patients with renal impairment (see PRECAUTIONS and CLINICAL PHARMACOLOGY). Close monitoring of hematologic parameters is advised in these patients.

Hepatic Insufficiency

SPL UNCLASSIFIED SECTION

There are no data that support specific guidance for dosage adjustment in patients with hepatic impairment. Close monitoring of hematologic parameters is advised in these patients.

HOW SUPPLIED

HOW SUPPLIED SECTION

Hydroxyurea capsules USP 500 mg are available as a two-piece hard gelatin capsule with purple opaque cap and pink opaque body filled with white powder, imprinted in black ink barr 882 and packaged in

Bottles of 30
NDC 54868-4773-0
Bottles of 40
NDC 54868-4773-4
Bottles of 50
NDC 54868-4773-2
Bottles of 60
NDC 54868-4773-3
Bottles of 100
NDC 54868-4773-1

Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

STORE IN A DRY ATMOSPHERE AND AVOID EXCESSIVE HEAT.

WEAR GLOVES AT ALL TIMES WHEN HANDLING CONTAINERS.

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

REFERENCES

REFERENCES SECTION

  1. NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.
  2. OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html
  3. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006;63:1172-1193.
  4. Polovich M, White JM, Kelleher LO, eds. 2005. Chemotherapy and biotherapy guidelines and recommendations for practice. 2nd ed. Pittsburgh, PA: Oncology Nursing Society.

TEVA PHARMACEUTICALS USA
Sellersville, PA 18960

Rev. A 2/2012

SPL UNCLASSIFIED SECTION

Relabeling and Repackaging by:
Physicians Total Care, Inc.
Tulsa, Oklahoma        74146

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Hydroxyurea Capsules USP 500 mg
Hydroxyurea Capsules USP 500 mg

Hydroxyurea Capsules USP 500 mg Label Text

SPL UNCLASSIFIED SECTION

HYDROXYUREA
Capsules USP
500 mg

Caution: Cytotoxic, Special
Handling Procedures

Rx only


DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
197797hydroxyurea 500 MG Oral CapsulePSN2
197797hydroxyurea 500 MG Oral CapsuleSCD2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
HYDROXYUREA Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9be3ebe6-89e5-4e2f-8781-a389e7eb49e7Product name120250129
f76fb619-09b6-d149-3287-3661f7bc38cdProduct name320250124
777d68c6-a5ab-e06c-d314-677b0b9af0c8Product name220240508
62a0eedf-9497-47af-bccf-d51b8b15b067Product name120180307

FDA-Initiated Inactive NDC Indexing#

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
54868-4773-0HYDROXYUREA30 in 1 BOTTLE, PLASTICCAPSULE302
54868-4773-1HYDROXYUREA100 in 1 BOTTLE, PLASTICCAPSULE1002
54868-4773-2HYDROXYUREA50 in 1 BOTTLE, PLASTICCAPSULE502
54868-4773-3HYDROXYUREA60 in 1 BOTTLE, PLASTICCAPSULE602
54868-4773-4HYDROXYUREA40 in 1 BOTTLE, PLASTICCAPSULE402

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
54868-4773HYDROXYUREA CAPSULE [PHYSICIANS TOTAL CARE, INC.]25 package rows20120619_7a2e2305-78bd-4077-96c6-59c5059201ab.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
54868-4773-0EA - Each54868-4773cb1a97e5-3510-4247-b64e-4363939e8b9112012-07-24
54868-4773-1EA - Each54868-477354571fc4-d727-4ac5-92c0-a6999bacc97412012-07-24
54868-4773-2EA - Each54868-47736d38e8fc-c4c0-4f02-98fd-1006fe7dc32a12012-07-24
54868-4773-3EA - Each54868-47736dab69a4-b33f-4a18-a90c-77449f6aff2412012-07-24
0555-0882-02EA - Each0555-08826f1fc549-d5a5-4c38-9499-d4fdbdc5fd8712012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
HYDROXYUREAACTIVE INGREDIENTX6Q56QN5QC2
HYDROXYUREAACTIVE MOIETYX6Q56QN5QC2
ALUMINUM OXIDEINACTIVE INGREDIENTLMI26O69332
ANHYDROUS CITRIC ACIDINACTIVE INGREDIENTXF417D3PSL2
BENZYL ALCOHOLINACTIVE INGREDIENTLKG8494WBH2
BUTYLPARABENINACTIVE INGREDIENT3QPI1U3FV82
CARBOXYMETHYLCELLULOSE SODIUMINACTIVE INGREDIENTK679OBS3112
D&C RED NO. 28INACTIVE INGREDIENT767IP0Y5NH2
D&C YELLOW NO. 10INACTIVE INGREDIENT35SW5USQ3G2
EDETATE CALCIUM DISODIUMINACTIVE INGREDIENT25IH6R4SGF2
FD&C BLUE NO. 1INACTIVE INGREDIENTH3R47K3TBD2
FD&C BLUE NO. 2INACTIVE INGREDIENTL06K8R7DQK2
FD&C RED NO. 40INACTIVE INGREDIENTWZB9127XOA2
FERRIC OXIDE REDINACTIVE INGREDIENT1K09F3G6752
FERROSOFERRIC OXIDEINACTIVE INGREDIENTXM0M87F3572
GELATININACTIVE INGREDIENT2G86QN327L2
LACTOSE MONOHYDRATEINACTIVE INGREDIENTEWQ57Q8I5X2
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I302
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9T2
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V32
PROPYLPARABEN SODIUMINACTIVE INGREDIENT625NNB0G9N2
SHELLACINACTIVE INGREDIENT46N107B71O2
SODIUM LAURYL SULFATEINACTIVE INGREDIENT368GB5141J2
SODIUM PHOSPHATE, DIBASICINACTIVE INGREDIENTGR686LBA742
SODIUM PROPIONATEINACTIVE INGREDIENTDK6Y9P42IN2
TITANIUM DIOXIDEINACTIVE INGREDIENT15FIX9V2JP2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 25 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
54868-477354868-4773-0, 54868-4773-1, 54868-4773-2, 54868-4773-3, 54868-4773-4
0555-0882

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 25 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 28 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
FERROSOFERRIC OXIDEFERROSOFERRIC OXIDEXM0M87F357CAPSULE / ORAL11 mgExact identifier — unii+route+dosage form
METHYLPARABENMETHYLPARABENA2I8C7HI9TCAPSULE / ORAL7 mgExact identifier — unii+route+dosage form
SODIUM PHOSPHATE, DIBASICSODIUM PHOSPHATE, DIBASICGR686LBA74SYRUP / ORAL70 mgExact identifier — unii+route
5 equally ranked IID candidates
TITANIUM DIOXIDETITANIUM DIOXIDE15FIX9V2JPCAPSULE / ORAL72 mgExact identifier — unii+route+dosage form
SODIUM LAURYL SULFATESODIUM LAURYL SULFATE368GB5141JCAPSULE / ORAL600 mgExact identifier — unii+route+dosage form
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE / ORAL256.4 mgExact identifier — unii+route+dosage form
EDETATE CALCIUM DISODIUMEDETATE CALCIUM DISODIUM25IH6R4SGFCAPSULE / ORALNAExact identifier — unii+route+dosage form
SODIUM PHOSPHATE, DIBASICSODIUM PHOSPHATE, DIBASICGR686LBA74FILM, SOLUBLE / ORAL9 mgExact identifier — unii+route
5 equally ranked IID candidates
D&C YELLOW NO. 10D&C YELLOW NO. 1035SW5USQ3GCAPSULE / ORAL20 mgExact identifier — unii+route+dosage form
ANHYDROUS CITRIC ACIDANHYDROUS CITRIC ACIDXF417D3PSLCAPSULE / ORAL131 mgExact identifier — unii+route+dosage form
SODIUM PROPIONATESODIUM PROPIONATEDK6Y9P42INCAPSULE / ORALNAExact identifier — unii+route+dosage form
FD&C BLUE NO. 2FD&C BLUE NO. 2L06K8R7DQKCAPSULE / ORAL4 mgExact identifier — unii+route+dosage form
FD&C BLUE NO. 1FD&C BLUE NO. 1H3R47K3TBDCAPSULE / ORAL26.3 mgExact identifier — unii+route+dosage form
FD&C RED NO. 40FD&C RED NO. 40WZB9127XOACAPSULE / ORAL16 mgExact identifier — unii+route+dosage form
CARBOXYMETHYLCELLULOSE SODIUMCARBOXYMETHYLCELLULOSE SODIUMK679OBS311CAPSULE / ORAL160 mgExact identifier — unii+route+dosage form
ALUMINUM OXIDEALUMINUM OXIDELMI26O6933TABLET / ORALNAExact identifier — unii+route
GELATINGELATIN2G86QN327LCAPSULE / ORAL10932 mgExact identifier — unii+route+dosage form
LACTOSE MONOHYDRATELACTOSE MONOHYDRATEEWQ57Q8I5XCAPSULE / ORAL3990 mgExact identifier — unii+route+dosage form
SODIUM PHOSPHATE, DIBASICSODIUM PHOSPHATE, DIBASICGR686LBA74CONCENTRATE / ORAL17 mg/5mlExact identifier — unii+route
5 equally ranked IID candidates
SODIUM PHOSPHATE, DIBASICSODIUM PHOSPHATE, DIBASICGR686LBA74SOLUTION / ORAL40 mg/1mlExact identifier — unii+route
5 equally ranked IID candidates
PROPYLPARABEN SODIUMPROPYLPARABEN SODIUM625NNB0G9NCAPSULE / ORAL1 mgExact identifier — unii+route+dosage form
BENZYL ALCOHOLBENZYL ALCOHOLLKG8494WBHCAPSULE / ORAL450 mgExact identifier — unii+route+dosage form
BUTYLPARABENBUTYLPARABEN3QPI1U3FV8CAPSULE / ORALNAExact identifier — unii+route+dosage form
FERRIC OXIDE REDFERRIC OXIDE RED1K09F3G675CAPSULE / ORAL5 mgExact identifier — unii+route+dosage form
SODIUM PHOSPHATE, DIBASICSODIUM PHOSPHATE, DIBASICGR686LBA74TABLET, EXTENDED RELEASE / ORAL143 mgExact identifier — unii+route
5 equally ranked IID candidates
SHELLACSHELLAC46N107B71OCAPSULE / ORAL34.48 mgExact identifier — unii+route+dosage form
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CAPSULE / ORAL1072 mgExact identifier — unii+route+dosage form
D&C RED NO. 28D&C RED NO. 28767IP0Y5NHCAPSULE / ORAL1 mgExact identifier — unii+route+dosage form

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A075143-001HYDROXYUREAHYDROXYUREA500MGCAPSULE / ORALAB1998-10-16
A075143-002HYDROXYUREAHYDROXYUREA250MGCAPSULE / ORAL2000-09-21

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A075143-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 3 · 90 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-16d4dbc9d85df4…
2026-11-14 07:37:172026-10A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-21d4dbc9d85df4…
2026-10-15 13:18:302026-09A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-16c2088c7a36db…
2026-10-15 13:18:302026-09A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-21c2088c7a36db…
2026-09-14 22:38:342026-08A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-1684e616aacf4f…
2026-09-14 22:38:342026-08A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-2184e616aacf4f…
2026-08-18 06:07:402026-07A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-16caaa826d4ba7…
2026-08-18 06:07:402026-07A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-21caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-16011fe1cb6892…
2026-02-19 14:30 UTC2026-02A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-21011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-1631067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-2131067a03dcf5…
2025-08-23 18:47 UTC2025-08A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-166a471c1ec25d…
2025-08-23 18:47 UTC2025-08A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-216a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-16fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-21fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-16b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-21b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-1603ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-2103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-162680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-212680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-165bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-215bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-16d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-21d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-16d06236e962d9…
2024-10-29 15:01 UTC2024-10A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-21d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-1679d66fd596c7…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-2179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-16301d65b070ca…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-21301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-161e350fbaab3a…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-211e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-168072bd15b7f6…
2024-05-31 18:47 UTC2024-05A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-218072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-165c6f7cd8ea54…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-215c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075143-001HYDROXYUREA500MGCAPSULE / ORALAB1998-10-165d02ea3f76ae…
2022-04-08 23:34 UTC2022-04A075143-002HYDROXYUREA250MGCAPSULE / ORAL2000-09-215d02ea3f76ae…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A075143-001AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09A075143-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08A075143-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A075143-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075143-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075143-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A075143-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075143-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075143-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075143-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075143-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075143-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075143-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075143-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075143-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075143-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075143-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075143-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075143-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075143-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A075143-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A075143-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A075143-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A075143-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A075143-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A075143-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A075143-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A075143-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A075143-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A075143-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A075143-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A075143-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A075143-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A075143-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A075143-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A075143-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A075143-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A075143-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A075143-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A075143-001AB13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
HYDROXYUREAHYDROXYUREATeva Pharmaceuticals USA, Inc.b9514ae5-79ae-4cc2-9d7f-c8f7806d16942024-05-30Warnings, Adverse reactionsExact identifier
ndc (product): 0555-0882
5d76dd07-6818-4ef2-9fa5-36c3d367f6dd7a2e2305-78bd-4077-96c6-59c5059201ab2012-06-01Warnings, Adverse reactionsExact identifier
spl id: 5d76dd07-6818-4ef2-9fa5-36c3d367f6dd
spl set id: 7a2e2305-78bd-4077-96c6-59c5059201ab

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.